Invasive aspergillosis a complication severe respiratory viral infections (influenza and COVID-19)

Invasive aspergillosis is a life-threatening complication in patients with severe influenza and COVID-19 in intensive care units. Risk factors for the invasive aspergillosis development are transitory immunosuppression associated with severe influenza and COVID-19, as well as the use of glucocorticosteroids and immunosuppressive therapy. In the presence of risk factors, suspected clinical and radiological signs of invasive aspergillosis, bronchoscopy and examination of material from the lower respiratory tract are necessary: test for galactomannan, microscopy with white calcofluor staining and inoculation on Sabouraud agar medium. Voriconazole or are recommended as first-line treatment for invasive aspergillosis in patients with severe influenza and COVID-19. Amphotericin B Liposomal, Amphotericin B Lipid Complex, and Caspofungin are the alternative options for the invasive aspergillosis treatment. Combination therapy is possible. It is necessary to control the underlying disease with eliminate or reduce the severity of risk factors.

Download Full-text

Life‐Threatening Adverse Event After Amphotericin B Lipid Complex Treatment in a Patient Treated Previously with Amphotericin B Deoxycholate

Clinical Infectious Diseases ◽

10.1086/517642 ◽

1998 ◽

Vol 26 (4) ◽

pp. 1016-1016 ◽

Cited By ~ 15

Author(s):

J. Garnacho‐Montero ◽

C. Ortiz‐Leyba ◽

J. L. García Garmendia ◽

F. J. Jiménez Jiménez

Keyword(s):

Adverse Event ◽

Amphotericin B ◽

Complex Treatment ◽

Lipid Complex ◽

Amphotericin B Deoxycholate ◽

Life Threatening ◽

Amphotericin B Lipid Complex

Download Full-text

Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex

Medical and Pediatric Oncology ◽

10.1002/mpo.2950250214 ◽

1995 ◽

Vol 25 (2) ◽

pp. 119-122 ◽

Cited By ~ 16

Author(s):

Duane R. Hospenthal ◽

John C. Byrd ◽

Raymond B. Weiss

Keyword(s):

Invasive Aspergillosis ◽

Amphotericin B ◽

Successful Treatment ◽

Acute Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Prolonged Treatment ◽

Lipid Complex ◽

Acute Myelogenous ◽

Amphotericin B Lipid Complex

Download Full-text

Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1700664 ◽

1997 ◽

Vol 19 (4) ◽

pp. 343-347 ◽

Cited By ~ 50

Author(s):

JR Wingard

Keyword(s):

Bone Marrow ◽

Amphotericin B ◽

Bone Marrow Transplant ◽

Marrow Transplant ◽

Transplant Recipients ◽

Lipid Complex ◽

Life Threatening ◽

Amphotericin B Lipid Complex

Download Full-text

Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B

American Journal of Health-System Pharmacy ◽

10.2146/ajhp120530 ◽

2013 ◽

Vol 70 (12) ◽

pp. 1047-1051 ◽

Cited By ~ 1

Author(s):

Mitchell S. Buckley ◽

Clint S. Anderson ◽

Shardool A. Patel ◽

Melanie J. Yerondopoulos ◽

Laura M. Wicks ◽

...

Keyword(s):

Invasive Aspergillosis ◽

Amphotericin B ◽

Adverse Reactions ◽

Cross Reactivity ◽

Alternative Formulation ◽

Lipid Complex ◽

Apparent Lack ◽

Course Of Action ◽

Amphotericin B Lipid Complex ◽

Alternative Lipid

Abstract Purpose The case of a patient who experienced probable infusion-related reactions to amphotericin B lipid complex (ABLC) but tolerated continued amphotericin B therapy after a switch to an alternative lipid-based formulation is reported. Summary A 28-year-old immunocompromised man with pneumonia, respiratory failure, and neutropenic fever was initiated on ABLC and other antibiotics for suspected invasive aspergillosis. Due to the patient’s deteriorating renal function, the use of amphotericin B was deemed preferable to the standard therapy for invasive aspergillosis (voriconazole) even though he had experienced likely infusion-related reactions to ABLC on two prior occasions. During the infusion of ABLC, significant increases in the man’s temperature, respiratory rate, systolic blood pressure, and heart rate were observed. Although those symptoms were suspected to be infusion related, it was decided that continuing amphotericin B therapy with an alternative lipid-based form of the drug was the best course of action. After the patient was switched to liposomal amphotericin B one day later, no further infusion-related adverse reactions were noted for the duration of therapy. While this case suggests that adverse reactions to one type of amphotericin B might not occur with the use of an alternative formulation, further research is needed to better define the potential for cross-reactivity among various forms of amphotericin B and related safe-infusion practices. Conclusion A patient with invasive aspergillosis who experienced likely infusion- related reactions to ABLC was able to tolerate continued amphotericin B therapy after a switch to the liposomal formulation.

Download Full-text